Skip to main content
Premium Trial:

Request an Annual Quote

Singular Genomics Inks Sample Prep Partnerships With Paragon Genomics, Claret Bioscience; Reports Q3

This story has been updated to correct the consensus Wall Street estimate for Singular Genomics' Q3 revenues.

NEW YORK – Singular Genomics Systems said on Monday that it has signed partnerships with Paragon Genomics and Claret Bioscience to validate its library preparation assays for use with the firm's G4 sequencer.

The announcement came as the firm reported its third quarter operating results. The San Diego-based sequencing technology firm continued to report no revenues, in line with the consensus Wall Street estimate, but said it will ship its first G4 sequencers in Q4. In August the firm reported that supply chain issues would impair its ability to scale up manufacturing of its sequencer as originally planned.

Singular's net loss for the quarter totaled $23.8 million, or $.33 per share, compared to a loss of $17.6 million, or $.25 per share, in Q3 2021, beating the consensus Wall Street estimate of a $.41 loss per share.

The firm reported $12.7 million in R&D expenses, up 43 percent year over year from $8.9 million. SG&A expenses were $12.0 million, up 40 percent from $8.6 million a year ago.

As of Sept. 30, Singular had $93.3 million in cash and cash equivalents and $170.6 million in short-term investments.

In Tuesday morning trading on the Nasdaq, shares of Singular were up 5 percent at $2.35.

Singular now has partnerships with more than half a dozen other companies on sequencing sample preparation.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.